Septic shock due to vancomycin-resistant enterococci infection. Tigecycline monotherapy;Septischer schock durch vancomycin-resistente enterokokken. Tigecyclin-monotherapie

Anaesthesist

Volumn 56, Issue 2, 2007, Pages 169-174

  Swoboda, S ^a   Hoppe Tichy, T ^a   Geiss, H K ^a   Hainer, C ^a   Nguyen, T H ^a   Knaebel, H P ^a   Weigand, M A ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Peritonitis; Pharmacodynamics; Pharmacokinetics; Septic shock; Vancomycin resistant enterococci

Indexed keywords

CILASTATIN PLUS IMIPENEM; EXTENDED SPECTRUM BETA LACTAMASE; NORADRENALIN; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ADULT; ANTIMICROBIAL THERAPY; APPENDICITIS; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; CASE REPORT; DIGESTIVE SYSTEM PERFORATION; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; HUMAN; INTESTINE PERFORATION; LAPAROTOMY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; PANCREAS SURGERY; PANCREATICODUODENECTOMY; PANCREATITIS; PERITONITIS; REOPERATION; SEPTIC SHOCK; TREATMENT INDICATION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; APACHE; ENTEROCOCCUS FAECIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; PANCREATITIS; PERITONITIS; SHOCK, SEPTIC; VANCOMYCIN RESISTANCE;

EID: 33847406097     PISSN: 00032417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00101-006-1088-2     Document Type: Article

References (35)

1. Angus DC, Wax RS (2001) Epidemiology of sepsis: an update. Crit Care Med 29: S109-116
2. Bodmann KF, Vogel F (2001) Antimikrobielle Therapie der Sepsis. Chemotherapie J 10: 43-56
3. Breedt J, Teras J, Gardovskis J et al. (2005) Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 49: 4658-4666
4. Clec'h C, Ferriere F, Karoubi P et al. (2004) Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med 32: 1166-1169
5. Conte JEJ, Golden JA, Kelly MG, Zurlinden E (2005) Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 25: 523-529
6. Dean CR, Visalli MA, Projan SJ et al. (2003) Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 47: 972-978
7. Dellinger RP, Carlet JM, Masur H et al. (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med 30: 536-555
8. Ellis-Grosse EJ, Babinchak T, Dartois N et al. (2005) The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41 [Suppl 5]: S341-353
9. Frampton JE, Curran MP (2005) Tigecycline. Drugs 65: 2623-2635
10. Friedman G, Silva E, Vincent JL (1998) Has the mortality of septic shock changed with time? Crit Care Med 26: 2078-2086
11. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A et al. (2003) Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 31: 2742-2751
12. Gotfried MH, Rodvold KA, Cwik M et al. (2005) An open label clinical evaluation of tigecycline (TGC) concentrations in selected tissues and fluids [abstract no. Lb-51]. Clin Pharmacol Ther 77: P98
13. Hirata T, Saito A, Nishino K et al. (2004) Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936). Antimicrob Agents Chemother 48: 2179-2184
14. Ibrahim EH, Sherman G, Ward S et al. (2000) The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118: 146-155
15. Iregui M, Ward S, Sherman G et al. (2002) Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 122: 262-268
16. Kollef MH, Sherman G, Ward S, Fraser VJ (1999) Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115: 462-474
17. Kumar A, Roberts D, Wood KE et al. (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34: 1589-1596
18. MacArthur RD, Miller M, Albertson T et al. (2004) Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis 38: 284-288
19. Muralidharan G, Micalizzi M, Speth J et al. (2005) Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 49: 220-229
20. Müller E (2006) Antibiotika bei Sepsis und Multiorganversagen. Intensivmedizin 43: 94-102
21. Noskin GA (2005) Tigecycline: a new glycylcycline for treatment of serious infections. Clin Infect Dis 41 [Suppl 5]: S303-314
22. Oliva ME, Rekha A, Yellin A et al. (2005) A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis 5: 88?99
23. Pankey GA (2005) Tigecycline. J Antimicrob Chemother 56: 470-480
24. Rubinstein E, Vaughan D (2005) Tigecycline: a novel glycylcycline. Drugs 65: 1317-1336
25. Ruzin A, Keeney D, Bradford PA (2005) AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob Agents Chemother 49: 791-793
26. Ruzin A, Visalli MA, Keeney D, Bradford PA (2005) Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother 49: 1017-1022
27. Solomkin JS, Mazuski JE, Baron EJ et al. (2003) Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 37: 997-1005
28. Sun HK, Ong CT, Umer A et al. (2005) Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 49: 1629-1632
29. Taccone FS, Rodriguez-Villalobos H, Backer D de et al. (2006) Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis 25: 257-260
30. Vincent JL, Sakr Y, Sprung CL et al. (2006) Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34: 344-353
31. Visalli MA, Murphy E, Projan SJ, Bradford PA (2003) AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 47: 665-669
32. Vogel F, Bodmann KF (2004) Empfehlungen zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen. Chemotherapie J 13: 46-105
33. Welte T (2004) Antibiotikatherapie der Sepsis. Dtsch Med Wochenschr 129: 2609-2613
34. Wheeler AP, Bernard GR (1999) Treating patients with severe sepsis. N Engl J Med 340: 207-214
35. Zhanel GG, Karlowsky JA, Rubinstein E, Hoban DJ (2006) Tigecycline: a novel glycylcycline antibiotic. Expert Rev Anti Infect Ther 4: 9-25